Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: Durvalumab plus tremelimumab (Dur/Tre) is a first-line systemic treatment option for unresectable hepatocellular carcinoma (uHCC). However, the management of severe immune-mediated adverse events (imAEs) is challenging. Therefore, we investigated the relationship between severe imAEs and antitumor responses in patients with uHCC treated with Dur/Tre. METHODS: We included 157 patients with uHCC treated with Dur/Tre in this multicenter, retrospective study and analyzed the relationship between progression-free survival (PFS)/antitumor response and severe imAEs requiring high-dose corticosteroid treatment. RESULTS: Thirty-two patients (20.4%) developed severe imAEs, including enterocolitis/diarrhea (n = 10), liver injury (n = 9), interstitial lung disease (n = 5), rashes (n = 4), cytokine-release syndrome/fever (n = 2), pancreatitis (n = 2), and others (n = 4) (median follow-up period, 6.8 months). Infliximab was administered in six patients with steroid-refractory enterocolitis. Although the objective response rate (ORR) and disease control rate (DCR) were significantly higher with first-line therapy than with later-line therapy (p = 0.026), the frequency of severe imAEs was not significantly different (p = 0.221). The ORR and DCR in patients with and without severe imAEs were 15.6% and 17.6% and 65.6% and 47.2%, respectively, with no significant differences. Five patients with severe imAEs, including rashes and liver injury, showed objective responses (partial response + complete response). Among patients who achieved an objective response, the PFS at 10 months was good (100% and 70.3% with and without high-dose corticosteroids, respectively). CONCLUSIONS: Severe imAEs of Dur/Tre treatment requiring high-dose corticosteroid treatment did not affect antitumor efficacy, which differed depending on the type of imAEs. Therefore, appropriately managing imAEs is essential to guide sequential treatment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
- Date Crossref
- 15/12/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya University Hospital Department of Gastroenterology and Hepatology pays non établi dans la noticeÉtablissement de santé
-
Kurume University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Kagawa University pays non établi dans la noticeUniversité ou école supérieure
-
Tokushima University Department of Gastroenterology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Yamaguchi University Department of Gastroenterology and Hepatology pays non établi dans la noticeUniversité ou école supérieure
-
Okayama University Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Gunma Saiseikai Maebashi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Kawasaki Medical School pays non établi dans la noticeUniversité ou école supérieure
-
National Hospital Organization Takasaki Medical Center pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Nagoya Daiichi Hospital pays non établi dans la noticeÉtablissement de santé
-
Toyohashi Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Anjo Kosei Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology and Hepatology — Nagoya University Hospital, Department of Medicine — Kurume University et Kagawa University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.